tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

NXTC Stock Latest News

NextCure files to sell 339,000 shares of common stock for holders
The FlyNextCure files to sell 339,000 shares of common stock for holders
2d ago
NXTC
NextCure price target lowered to $15 from $36 at Piper Sandler
PremiumThe Fly
NextCure price target lowered to $15 from $36 at Piper Sandler
6d ago
NXTC
NextCure Implements Reverse Stock Split on Nasdaq
PremiumCompany Announcements
NextCure Implements Reverse Stock Split on Nasdaq
7d ago
8K
NXTC
Upcoming Stock Splits This Week (July 14 to July 18) – Stay Invested
PremiumMarket News
Upcoming Stock Splits This Week (July 14 to July 18) – Stay Invested
8d ago
GORV
HTOO
NextCure trading halted, news pending
PremiumThe Fly
NextCure trading halted, news pending
9d ago
NXTC
NextCure Announces One-for-Twelve Reverse Stock Split
PremiumCompany AnnouncementsNextCure Announces One-for-Twelve Reverse Stock Split
11d ago
8K
NXTC
NextCure Approves Key Decisions at Annual Meeting
Premium
Company Announcements
NextCure Approves Key Decisions at Annual Meeting
28d ago
8K
NXTC
NextCure Enters Licensing Agreement with Simcere Zaiming
Premium
Company Announcements
NextCure Enters Licensing Agreement with Simcere Zaiming
1M ago
8K
NXTC
NextCure, Simcere Zaiming announce strategic partnership
PremiumThe Fly
NextCure, Simcere Zaiming announce strategic partnership
1M ago
NXTC
Buy Rating Affirmed for NextCure: Promising LNCB74 Trial Progress and Competitive Edge in B7-H4 ADC Landscape
PremiumRatings
Buy Rating Affirmed for NextCure: Promising LNCB74 Trial Progress and Competitive Edge in B7-H4 ADC Landscape
3M ago
NXTC
NextCure Reports Q1 2025 Results and Strategic Progress
PremiumCompany Announcements
NextCure Reports Q1 2025 Results and Strategic Progress
3M ago
NXTC
NextCure reports Q1 EPS (39c), consensus (40c)
PremiumThe Fly
NextCure reports Q1 EPS (39c), consensus (40c)
3M ago
NXTC
NextCure Updates Presentation on LNCB74 Clinical Trial
PremiumCompany AnnouncementsNextCure Updates Presentation on LNCB74 Clinical Trial
3M ago
8K
NXTC
Optimistic Buy Rating for NextCure Driven by Promising Developments in LNCB74 for Endometrial Cancer
Premium
Ratings
Optimistic Buy Rating for NextCure Driven by Promising Developments in LNCB74 for Endometrial Cancer
4M ago
NXTC
H.C. Wainwright says competitor data builds optimism for NextCure’s LNCB74
Premium
The Fly
H.C. Wainwright says competitor data builds optimism for NextCure’s LNCB74
4M ago
AZN
PFE
Nextcure Faces Delisting Risk Amid Nasdaq Compliance Struggles
PremiumCompany Announcements
Nextcure Faces Delisting Risk Amid Nasdaq Compliance Struggles
5M ago
NXTC
NextCure Reports 2024 Financials and Strategic Progress
PremiumCompany Announcements
NextCure Reports 2024 Financials and Strategic Progress
5M ago
NXTC
NextCure’s Promising Trajectory: Buy Rating Backed by Clinical Progress and Competitive Edge
PremiumRatings
NextCure’s Promising Trajectory: Buy Rating Backed by Clinical Progress and Competitive Edge
5M ago
NXTC
NextCure announces first patient dosed in Phase 1 study of LNCB74
PremiumThe Fly
NextCure announces first patient dosed in Phase 1 study of LNCB74
6M ago
NXTC
NextCure announces acceptance of IND application for LNCB74
PremiumThe FlyNextCure announces acceptance of IND application for LNCB74
7M ago
NXTC
NextCure Advances with New Cancer Drug Application
Premium
Company Announcements
NextCure Advances with New Cancer Drug Application
8M ago
8K
NXTC
NextCure announces preclinical data on NC605
Premium
The Fly
NextCure announces preclinical data on NC605
8M ago
NXTC

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >